Bioequivalence study of CRUshed Sofosbuvir/velpAtasvir compareD to the wholE tablet (CRUSADE-1)/Hep-NED004
Latest Information Update: 07 Apr 2022
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics; Pharmacokinetics
- Acronyms CRUSADE-1
- 06 Apr 2022 This trial has been completed in Netherlands (Date of the global end of the trial : 22-Mar-2019), according to European Clinical Trials Database record.
- 05 Aug 2019 Planned End Date changed from 1 Dec 2020 to 22 Mar 2019.
- 05 Aug 2019 Planned primary completion date changed from 1 Dec 2020 to 22 Mar 2019.